Phase 2
N=21
Twice Weekly Steroids and Exercise as Therapy for DMD
Duchenne Muscular Dystrophy (DMD)
Bottom Line
View on ClinicalTrials.gov: NCT04322357 ↗Enrolled (actual)
21
Serious AEs
4.8%
Results posted
Mar 2026
Primary outcome: Primary: Change in BMI — 0.67; 1.34; 1.8 kg/m^2
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Prednisone (Drug); Exercise Training on standard steroid regimen (Behavioral); Exercise training on twice-weekly steroids (Drug)
- Age
- Pediatric · 5+ yrs
- Sex
- Male
- Sponsor
- University of Florida
- Primary completion
- Dec 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in BMI |
0.67; 1.34; 1.8 | — |
Summary
The study team will determine the potential of low dose twice weekly prednisone and whether exercise training can synergize to delay disease progression and improve muscle strength/physical function in boys with Duchenne muscular dystrophy (DMD). Current standard of care (daily prednisone) is associated with adverse side effects. Evidence from DMD mouse models suggest that weekly dosing provides same efficacy without side effects. Appropriate exercise may also benefit but this area has not been adequately explored.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of DMD confirmed by 1) clinical history with features before the age of five, 2) physical examination, 3) elevated serum creatine kinase level and 4) absence of dystrophin expression, as determined by immunostain or Western blot (<2%) and/or DNA confirmation of dystrophin mutation.
- Age 5.0 to 9 years: a lower age limit of 5.0 years is selected as children younger than that are likely unable to cooperate and comply with all of the exercise measures as needed. An upper age limit of 9 years has been set as boys with DMD tend to reach a rapid progression into a late ambulatory phase soon after this age.
- Ambulatory at the time of the first visit, defined as the ability to walk for at least 100 m without an external assistive device and able to climb four stairs.
- Aim 1 only: GC-naïve at baseline (and prior 6 months)
- Aim 2 only: on stable daily GC regimen for 6 months prior to baseline
Exclusion Criteria
- Contraindication to an MR examination (e.g. aneurysm clip, severe claustrophobia, magnetic implants)
- Presence of unstable medical problems, significant concomitant illness including cardiomyopathy or cardiac conduction abnormalities
- Presence of a secondary condition that impacts muscle function or muscle metabolism (e.g. myasthenia gravis, endocrine disorder, mitochondrial disease)
- Presence of a secondary condition leading to developmental delay or impaired motor control (e.g. cerebral palsy)
- Presence of an unstable medical condition (e.g. uncontrolled seizure disorder)
- Behavioral problems causing an inability to cooperate during testing or understand exercise instruction
- Participation in other forms of drug or gene therapy during the period of the study
Data sourced from ClinicalTrials.gov (NCT04322357). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.